ASCO® 2026 Highlights: Presenter Vignette – Ahmad Tarhini

Dr. Ahmad Tarhini

Ahmad Tarhini

MD, PhD

Moffitt Cancer Center

9501

A phase II study of neoadjuvant ipilimumab-nivolumab-relatlimab (INR) combination immunotherapy in high-risk resectable melanoma.